Metraipolis › archive › dc_c2879ee02c7d

Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation Strategies — Europe PMC PMID:41744848

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41744848
DOI
10.3390/curroncol33020084
License (as archived)
solo-consultazione
Archived
2026-11-06T09:31:37.300Z
SHA-256 of the archived text
fe4e1644636bb9a7bad1d988653aee796451057483db36e65995ad6647feb1e8
Stable URL of this page
https://metraipolis.com/documento/dc_c2879ee02c7d

How to cite

Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation Strategies — Europe PMC PMID:41744848 — Europe PMC (en), https://europepmc.org/article/MED/41744848 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c2879ee02c7d (Metraipolis archive dc_c2879ee02c7d, sha256 fe4e1644636bb9a7bad1d988653aee796451057483db36e65995ad6647feb1e8)
BibTeX
@misc{dcc2879ee02c7d,
  title = {Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation Strategies — Europe PMC PMID:41744848},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41744848},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c2879ee02c7d; sha256 fe4e1644636bb9a7bad1d988653aee796451057483db36e65995ad6647feb1e8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41744848. Agents can read the archived copy with the MCP tool read_document.